Dr. Brian E. Lewis, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 61
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Tulane University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
LA license MD.201255
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- East Jefferson General Hospital Metairie, LA
Medical groups
- Administrators of the Tulane Educational Fund (393 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 61
- Services billed
- 187
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 131 | 46 |
| Established patient office or other outpatient visit, 10-19 minutes | 57 | 40 |
| Established patient office or other outpatient visit, 30-39 minutes | 50 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 215 |
| Prednisone Other prescribers in New Orleans, LA | 139 |
| Xtandi (enzalutamide) | 67 |
| Dexamethasone Other prescribers in New Orleans, LA | 48 |
| Inlyta (axitinib) | 29 |
| Orgovyx (relugolix) | 29 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in New Orleans, LA | 24 |
| Tamsulosin Hcl Other prescribers in New Orleans, LA | 14 |
| Erleada (apalutamide) | 13 |
| Cabometyx (cabozantinib s-malate) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 11 payments worth $262 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $87.29 |
|---|---|
| Gilead Sciences, Inc. | $42.71 |
| Pfizer Inc. | $41.96 |
| Aveo Pharmaceuticals, Inc. | $28.27 |
| Astellas Pharma US Inc | $25.61 |
| EMD Serono, Inc. | $22.10 |
| Dendreon Pharmaceuticals LLC | $13.81 |
| Food and Beverage | $262 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 8 companies. The companies reported $333,145 in research payments for these studies, mostly to the institutions running them.
- An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals Corporation - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
Aveo Pharmaceuticals, Inc. · Completed · NCT04987203 - A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Inelig…
Merck Sharp & Dohme LLC - A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer
Janssen Research & Development, LLC - A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Pfizer Inc. - Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)
Eli Lilly and Company - A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer
Novartis Pharmaceuticals Corporation - A Phase III Randomized Open-Label Controlled Multi-Center Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Ch…
AstraZeneca Pharmaceuticals LP - A randomized openlabel phase 3 trial of tisotumab vedotin vs investigators choice chemotherapy in second or thirdline recurrent or metastatic cervical cancer
Pfizer Inc. - A phase III randomized, double-blind, multi-center study of adjuvant nivolumab versus placebo in subjects with high risk invasive urothelial carcinoma
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.